临床误诊误治2016，Vol.29Issue(3)：109-112,4.DOI:10.3969/j.issn.1002-3429.2016.03.036
艾塞那肽对2型糖尿病患者血清内脏脂肪素的影响
Impact of Exenatide Injection on Serum Visfatin Level in Patients with Type 2 Diabetes
摘要
Abstract
Objective To investigate the effect of Exenatide and Alogliptin on serum visfatin levels and blood glucose concentrations. Methods 80 T2DM patients were randomly divided into two groups: Alogliptin benzoate tablet group (25 mg/d, oral administration, n=40) and Exenatide group (10 μg, subcutaneous injection, n=40). After 12 weeks of treatment, BMI, FPG, HbA1C, FIN, HOMA-IR, CRP, blood pressure, and serum visfatin levels were measured and com-pared between the two groups with those of pretherapy. Results FPG, 2hPG, FIN, P2hIN, HbA1C, HOMA-IR and CRP were markedly improved in both the two group. However, only Exenatide group showed significantly decreased serum Visfatin levels which were positively correlated with BMI, FBG, HbA1C, CRP, FIN, and HOMA-IR (P <0. 05). There was no difference of Visfatin levels in Alogliptin benzoate table group and anlysis showed that HbA1C, FIN, HOMA-IR, and CRP were independent factors associated with visfatin element (P<0. 05). Conclusion In patients with type 2 diabetes, visfatin levels may increase significantly. Exenatide injection can obviously improve insulin resistance and decrease serum Visfatin concentrations. HbA1C, FIN, HOMA-IR, and CRP are independent factors associated with Visfatin element.关键词
内脏脂肪素/糖尿病,2型/阿格列汀/艾塞那肽Key words
Visfatin/Diabetes mellitus/type 2/Alogliptin/Exenatide分类
医药卫生引用本文复制引用
李丹丹..艾塞那肽对2型糖尿病患者血清内脏脂肪素的影响[J].临床误诊误治,2016,29(3):109-112,4.基金项目
2015年卫计委科研课题计划项目[沈卫办(2015)478] （2015）
